title: [Anti-glioma effect of combination of bFGF-siRNA and Vpr in nude mice].
abstract: OBJECTIVE
  To study the anti-glioma effect of recombinant adenovirus mediated combined gene therapy of bFGF-siRNA and HIV1-Vpr in vivo.
  
  
  METHODS
  Mouse glioma model was established by injecting 5 × 10(6) LN229 cells into BALB/c-nu nude mice. 30 nude mice were randomly divided into 5 groups: the negative control group, mock group, bFGF-siRNA group, Vpr group and combined therapy group, which at regular intervals were injected with PBS, rAd5-null, rAd5-bFGF-siRNA, rAd5-Vpr, rAd5-bFGF-siRNA plus rAd5-Vpr, respectively. The tumor volume was recorded every third day to draw a growth curve. After four weeks treatment, the mice were killed and specimens were taken. HE, immunohistochemical and TUNEL staining were performed to observe the cell morphology, detect the changes of relevant target proteins and cell apoptosis, respectively. Also the ultrastructural changes were observed by electron microscopy.
  
  
  RESULTS
  The tumor growth inhibition rates were 36.9%, 37.2% and 58.6% in the bFGF-siRNA group, Vpr group and combined therapy group, respectively, and the combined therapy group showed the most significant effect (P < 0.05). Also the results of HE, immunohistochemical and TUNEL staining revealed that the combined therapy group had the best effects on proliferation inhibition and apoptosis induced in glioma cells (P < 0.05). The most significant ultrastructural changes were observed in the combined therapy group.
  
  
  CONCLUSIONS
  The combined gene therapy of bFGF-siRNA with Vpr shows a prominent and synergistic anti-glioma effect compared with that of mono-gene therapy in nude mice.
authors.affiliation: Department of Neurosurgery, Tianjin First Central Hospital, Tianjin 300192, China.
authors.forename: Xue-quan
authors.initials: XQ
authors.lastname: Feng
authors.forename: Jin-huan
authors.initials: JH
authors.lastname: Wang
authors.forename: Xin-nü
authors.initials: XN
authors.lastname: Xu
authors.forename: Biao
authors.initials: B
authors.lastname: Zhang
authors.forename: Shu-jie
authors.initials: SJ
authors.lastname: Wang
authors.forename: Hong-sheng
authors.initials: HS
authors.lastname: Liu
authors.forename: Na
authors.initials: N
authors.lastname: Lin
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D017209:Apoptosis; D001932:Brain Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D016222:Fibroblast Growth Factor 2 / Q000235:genetics* / Q000378:metabolism; D016336:Gene Products, vpr / Q000235:genetics* / Q000378:metabolism; D015316:Genetic Therapy; D005910:Glioma / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D034741:RNA, Small Interfering / Q000235:genetics*; D011897:Random Allocation; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism
chemical_list: D016336:Gene Products, vpr; D034741:RNA, Small Interfering; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2